Richard Harding1, Irene J Higginson. 1. King's College London, Department of Palliative Care, Policy and Rehabilitation, School of Medicine at Guy's King's and St. Thomas Hospitals, Cicely Saunders Institute, Bessemer Road, London SE5 9PJ, UK. richard.harding@kcl.ac.uk
Abstract
INTRODUCTION: The epidemiology of progressive cancer and associated mortality in Europe underlines the essential need for high quality palliative and end-of-life care for its citizens. Currently, care of patients at the end-of-life is under-researched and under-funded. This is due to a lack of prioritisation, challenges in defining end-of-life, lack of a common research strategy for Europe that identifies and implements best practice and highest scientific principles, and the need for common use of appropriate well-validated tools to measure and improve the end-of-life cancer experience in Europe. METHODS: PRISMA is a pan-European co-ordinating action funded under Framework Programme 7 of the European Commission. With 12 partners in 9 countries, it is delivering a series of 8 Work Packages with the common aim of promoting best practice in the measurement of end-of-life care, setting an agenda and guidance that reflects European cultural diversity, and is informed by both public and clinical priorities. Guidance in the selection, adaptation and use of core tools is informed by experts in public health and clinical research. DISCUSSION: PRISMA is currently producing a series of outputs to be accessible to the wider community of researchers, policy makers, funders and clinicians. We encourage new partnerships to build on the work of PRISMA and to lead high quality work informed by our deliverables. PRISMA, we hope, is redressing the current lack of co-ordination of cancer end-of-life research across Europe, and will catalyse the conduct of evidence-based care that reflects European populations and priorities. Copyright 2010 Elsevier Ltd. All rights reserved.
INTRODUCTION: The epidemiology of progressive cancer and associated mortality in Europe underlines the essential need for high quality palliative and end-of-life care for its citizens. Currently, care of patients at the end-of-life is under-researched and under-funded. This is due to a lack of prioritisation, challenges in defining end-of-life, lack of a common research strategy for Europe that identifies and implements best practice and highest scientific principles, and the need for common use of appropriate well-validated tools to measure and improve the end-of-life cancer experience in Europe. METHODS: PRISMA is a pan-European co-ordinating action funded under Framework Programme 7 of the European Commission. With 12 partners in 9 countries, it is delivering a series of 8 Work Packages with the common aim of promoting best practice in the measurement of end-of-life care, setting an agenda and guidance that reflects European cultural diversity, and is informed by both public and clinical priorities. Guidance in the selection, adaptation and use of core tools is informed by experts in public health and clinical research. DISCUSSION: PRISMA is currently producing a series of outputs to be accessible to the wider community of researchers, policy makers, funders and clinicians. We encourage new partnerships to build on the work of PRISMA and to lead high quality work informed by our deliverables. PRISMA, we hope, is redressing the current lack of co-ordination of cancer end-of-life research across Europe, and will catalyse the conduct of evidence-based care that reflects European populations and priorities. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Barbara A Daveson; Dorothee Bechinger-English; Claudia Bausewein; Steffan T Simon; Richard Harding; Irene J Higginson; Barbara Gomes On Behalf Of Prisma Journal: J Palliat Med Date: 2011-02-09 Impact factor: 2.947
Authors: Steffen T Simon; Irene J Higginson; Richard Harding; Barbara A Daveson; Marjolein Gysels; Luc Deliens; Michael A Echteld; Lukas Radbruch; Franco Toscani; Dominik M Krzyzanowski; Massimo Costantini; Julia Downing; Pedro L Ferreira; Abdelhamid Benalia; Claudia Bausewein Journal: Support Care Cancer Date: 2012-03-07 Impact factor: 3.603
Authors: Barbara Gomes; Paul McCrone; Sue Hall; Julia Riley; Jonathan Koffman; Irene J Higginson Journal: Support Care Cancer Date: 2013-06-08 Impact factor: 3.603
Authors: Julia Downing; Steffen T Simon; Faith N Mwangi-Powell; Hamid Benalia; Barbara A Daveson; Irene J Higginson; Richard Harding; Claudia Bausewein Journal: BMC Palliat Care Date: 2012-01-06 Impact factor: 3.234
Authors: Anthony Byrne; Anna Torrens-Burton; Stephanie Sivell; Fabio Ynoe Moraes; Helen Bulbeck; Mark Bernstein; Annmarie Nelson; Helen Fielding Journal: Cochrane Database Syst Rev Date: 2022-01-06
Authors: Claudia Bausewein; Steffen T Simon; Hamid Benalia; Julia Downing; Faith N Mwangi-Powell; Barbara A Daveson; Richard Harding; Irene J Higginson Journal: Health Qual Life Outcomes Date: 2011-04-20 Impact factor: 3.186
Authors: Katrin Ruth Sigurdardottir; Dagny Faksvåg Haugen; Claudia Bausewein; Irene J Higginson; Richard Harding; Jan Henrik Rosland; Stein Kaasa Journal: Support Care Cancer Date: 2010-11-30 Impact factor: 3.603
Authors: Claudia Bausewein; Natalia Calanzani; Barbara A Daveson; Steffen T Simon; Pedro L Ferreira; Irene J Higginson; Dorothee Bechinger-English; Luc Deliens; Marjolein Gysels; Franco Toscani; Lucas Ceulemans; Richard Harding; Barbara Gomes Journal: BMC Cancer Date: 2013-03-08 Impact factor: 4.430